ACST Stock – (NASDAQ: ACST) is actually providing an update on the usage
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or perhaps the “Company”) ACST Stock (NASDAQ: ACST – TSX-V: ACST) is actually providing an update on the use of its “at-the market” equity providing program.
As earlier disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. along with H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to carry out an “at-the market” equity offering system under which Acasti might issue as well as sell from time to time the everyday shares of its having an aggregate offering price of up to seventy five dolars million throughout the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the end distributions reported on January 27, 2021, Acasti given an aggregate of 20,159,229 typical shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 million. The ATM Shares had been offered at prevailing market costs averaging US$1.0747 a share. No securities had been sold throughout the facilities of the TSXV or, to the expertise of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S 3 (No. 333-239538) as made effective on July 7, 2020, and the Sales Agreement. Pursuant to the Sales Agreement, a cash commission of 3.0 % on the aggregate gross proceeds raised was paid to the Agents in connection with their services. As a result of the recent ATM sales, Acasti has a total of 200,119,659 typical shares issued and great as of March 5, 2021.
The additional capital raised has strengthened Acasti’s balance sheet and will provide the Company with extra freedom in its continuous review process to check out and evaluate strategic options.
About Acasti – ACST Stock
Acasti is actually a biopharmaceutical innovator that has historically centered on the research, development and commercialization of prescribed drugs making use of OM3 fatty acids delivered both as totally free fatty acids and bound-to-phospholipid esters, created from krill oil. OM3 fatty acids have extensive clinical evidence of efficacy and safety in lowering triglycerides in patients with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being developed for individuals with serious HTG.
Forward Looking Statements – ACST Stock
Statements in that press release that aren’t statements of historical or current fact constitute “forward looking information” to the meaning of Canadian securities laws as well as “forward-looking statements” within the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward looking assertions include known and unknown risks, uncertainties, along with other unknown factors that might result in the particular outcomes of Acasti to be materially different from historical results and from any future outcomes expressed or implied by such forward looking statements. In addition to statements which explicitly describe these kinds of risks as well as uncertainties, readers are urged to look at statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or other related expressions to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward looking statements, which speak just as of the day of this press release. Forward-looking claims in that press release include, but aren’t limited to, statements or information about Acasti’s strategy, future operations and the review of its of strategic alternatives.
The forward looking statements found in this specific press release are expressly qualified in their entirety by this alerting statement, the “Special Note Regarding Forward-Looking Statements” section contained in Acasti’s latest annual report on Form 10 K and quarterly report on Form 10-Q, which are readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com and also on the investor section of Acasti’s site at www.acastipharma.com. Most forward-looking statements in that press release are produced as of the particular date of this particular press release.
ACST Stock – Acasti does not undertake to upgrade any such forward looking statements whether as a direct result of new information, future events or perhaps otherwise, except as needed by law. The forward-looking claims contained herein are also subject generally to assumptions and risks and uncertainties that are described from time to time in Acasti’s public securities filings with the Securities as well as exchange Commission and The Canadian securities commissions, like Acasti’s newest annual report on Form 10-K and quarterly report on Form 10-Q under the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is giving an update on the use